Candida auris: Epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area, January 2018 to May 2019
Plachouras, D., Lötsch, F., Kohlenberg, A., Monnet, D.L., Lass-Flörl, C., Muchl, R., Willinger, B., Lagrou, K., Philipova, I., Budimir, A., Hadjihannas, L., Arendrup, M.C., Märtin, P., Lyytikäinen, O., Jalava, J., Dromer, F., Kurzai, O., Vrioni, G., Kontopidou, F., Kurcz, A., Zala, J., Sigmundsdottir, G., Burns, K., Moro, M.L., Vulane, K., Valinteliene, R., Perrin, M., Scicluna, E.A., De Greeff, S., Kacelnik, O., Deptula, A., Do Rosário Rodrigues, M., Serban, R., Stefkovicová, M., Serdt, M., Alastruey-Izquierdo, A., Berciano, P.G., Byfors, S., Brown, C.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
Candida auris in healthcare settings
Due to its propensity to cause outbreaks and its antifungal resistance, C. auris poses a risk for patients in healthcare facilities in Europe. Difficulties with laboratory identification, combined with a lack of awareness of this new Candida species, might result in unnoticed outbreaks. There is a clear need to raise awareness in European healthcare facilities in order adapt laboratory testing strategies and implement enhanced control measures to prevent further hospital outbreaks.